Johannes J.M. Rood

Bisubstrate Inhibitors of Nicotinamide <i>N</i>-Methyltransferase (NNMT) with Enhanced Activity

Yongzhi Gao, Matthijs J. van Haren, Ed E. Moret et al. · Journal of Medicinal Chemistry · 2019 · 68 citations · Full text

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

Stéphanie van Hoppe, Amer Jamalpoor, Johannes J.M. Rood et al. · Pharmacological Research · 2019 · 46 citations

Molecular Neuroscience, Glioma, Medicine +8

Liquid chromatography–tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies

Johannes J.M. Rood, Stéphanie van Hoppe, Alfred H. Schinkel et al. · Journal of Pharmaceutical and Biomedical Analysis · 2015 · 45 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Pharmacological Study +11

Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma

Johannes J.M. Rood, Mark T. J. van Bussel, Jan H.M. Schellens et al. · Journal of Chromatography B · 2016 · 42 citations · Full text

Therapeutic Drug Monitoring, Sclerostin, Medicine +6

Liquid chromatographytandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O desmethyl metabolites of erlotinib and gefitinib in human plasma

Rolf W. Sparidans, Hilde Rosing, Johannes J.M. Rood et al. · Journal of Chromatography B · 2016 · 34 citations · Full text